Chen Xiao-Long, Jiang Mi-Zu
Department of Gastroenterology and Pediatric Endoscopy Center, Children's Hospital, Zhejiang University School of Medicine/National Clinical Research Center for Child Health/National Children's Regional Medical Center, Hangzhou 310052, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2024;26(9):989-994. doi: 10.7499/j.issn.1008-8830.2404130.
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by symptoms such as abdominal pain, diarrhea, constipation, and indigestion. Given its unclear etiology and pathogenesis, and the absence of specific biomarkers, clinical diagnosis and treatment of IBS continue to pose significant challenges. In recent years, metabolomics technology, known for its non-invasive, high-throughput, high-precision, and highly reproducible features, has been widely applied in the diagnosis, treatment, and prognosis of various diseases. Therefore, metabolomics technology is expected to offer novel insights and methodologies for the biological mechanism research, diagnosis, and treatment of IBS. This article reviews recent advancements in the application of metabolomics to IBS, exploring its potential value in the clinical diagnosis and treatment of children with this condition.
肠易激综合征（IBS）是一种常见的功能性胃肠疾病，其特征为腹痛、腹泻、便秘和消化不良等症状。鉴于其病因和发病机制尚不明确，且缺乏特异性生物标志物，IBS的临床诊断和治疗仍然面临重大挑战。近年来，以无创、高通量、高精度和高重复性为特点的代谢组学技术已广泛应用于各种疾病的诊断、治疗和预后评估。因此，代谢组学技术有望为IBS的生物学机制研究、诊断和治疗提供新的见解和方法。本文综述了代谢组学在IBS应用中的最新进展，探讨其在该病患儿临床诊断和治疗中的潜在价值。
